160 related articles for article (PubMed ID: 28388591)
21. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
[TBL] [Abstract][Full Text] [Related]
22. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Speirs CK; Simpson JR; Robinson CG; DeWees TA; Tran DD; Linette G; Chicoine MR; Dacey RG; Rich KM; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):268-76. PubMed ID: 25636755
[TBL] [Abstract][Full Text] [Related]
23. Tumor cell-specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma.
Jiang H; Zhang Z; Ren X; Zeng W; Wang J; Lin S
J Neurosurg; 2016 Oct; 125(4):995-1001. PubMed ID: 26771849
[TBL] [Abstract][Full Text] [Related]
24. Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms.
Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; Kopitzki K; du Plessis DG; Prosser J; Vinjamuri S; Warnke PC
Br J Cancer; 2006 Nov; 95(10):1424-31. PubMed ID: 17031404
[TBL] [Abstract][Full Text] [Related]
25. [The oligodendroglioma: the value of histologic and genetic diagnosis in predicting sensitivity to chemotherapy].
Kros JM
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1379-85. PubMed ID: 15997690
[TBL] [Abstract][Full Text] [Related]
26. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Cairncross G; Wang M; Shaw E; Jenkins R; Brachman D; Buckner J; Fink K; Souhami L; Laperriere N; Curran W; Mehta M
J Clin Oncol; 2013 Jan; 31(3):337-43. PubMed ID: 23071247
[TBL] [Abstract][Full Text] [Related]
27. A multi-institutional analysis of clinical outcomes and patterns of care of 1p/19q codeleted oligodendrogliomas treated with adjuvant or salvage radiation therapy.
Lin AJ; Kane LT; Molitoris JK; Smith DR; Dahiya S; Badiyan SN; Wang TJC; Kruser TJ; Huang J
J Neurooncol; 2020 Jan; 146(1):121-130. PubMed ID: 31741234
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
29. Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma.
Khan KA; Abbasi AN; Ali N
J Coll Physicians Surg Pak; 2014 Dec; 24(12):935-9. PubMed ID: 25523732
[TBL] [Abstract][Full Text] [Related]
30. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
[TBL] [Abstract][Full Text] [Related]
31. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
[TBL] [Abstract][Full Text] [Related]
32. Genetic and epigenetic stability of oligodendrogliomas at recurrence.
Aihara K; Mukasa A; Nagae G; Nomura M; Yamamoto S; Ueda H; Tatsuno K; Shibahara J; Takahashi M; Momose T; Tanaka S; Takayanagi S; Yanagisawa S; Nejo T; Takahashi S; Omata M; Otani R; Saito K; Narita Y; Nagane M; Nishikawa R; Ueki K; Aburatani H; Saito N
Acta Neuropathol Commun; 2017 Mar; 5(1):18. PubMed ID: 28270234
[TBL] [Abstract][Full Text] [Related]
33. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
34. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
[TBL] [Abstract][Full Text] [Related]
35. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
[TBL] [Abstract][Full Text] [Related]
36. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.
Reifenberger J; Reifenberger G; Liu L; James CD; Wechsler W; Collins VP
Am J Pathol; 1994 Nov; 145(5):1175-90. PubMed ID: 7977648
[TBL] [Abstract][Full Text] [Related]
37. Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.
Anderson MD; Gilbert MR
Oncology (Williston Park); 2013 Apr; 27(4):315-20, 322. PubMed ID: 23781695
[TBL] [Abstract][Full Text] [Related]
38. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
[TBL] [Abstract][Full Text] [Related]
39. Low-grade and anaplastic oligodendroglioma.
Van Den Bent MJ; Bromberg JE; Buckner J
Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366
[TBL] [Abstract][Full Text] [Related]
40. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Kouwenhoven MC; Kros JM; French PJ; Biemond-ter Stege EM; Graveland WJ; Taphoorn MJ; Brandes AA; van den Bent MJ
Eur J Cancer; 2006 Oct; 42(15):2499-503. PubMed ID: 16914310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]